A Weizmann Institute-led international team of researchers has found how bacteria in the gut microbiome affects the body’s response to cancer immunotherapy (see also here previously). Also, patients treated with specific antibiotics had a poor response to CAR-T cancer treatment. … Continue reading →

20-year-old Kalim was sent home from hospital to die in St Petersburg after doctors said they could not treat his acute lymphoblastic leukemia. He immigrated to Israel where five months of CAR-T treatment at Rambam Health Care Campus gave Kalim … Continue reading →

Scientists at Jerusalem’s Hadassah hospital and Bar-Ilan University have developed HBI0101- a CAR-T therapy for multiple myeloma and amyloidosis, benefiting over 90% of patients in trials. Los Angeles-based Immix BioPharma will commercialize HBI0101. https://www.timesofisrael.com/after-demonstrating-57-remission-rate-israeli-immunotherapy-licensed-by-us-firm/ https://haematologica.org/article/view/haematol.2022.281628

Israel’s ImmPACT Bio is developing transformative logic-gate-based CAR-T cell therapies for cancer patients who have exhausted their treatment options. The technology is designed to distinguish cancerous cells from normal cells, thereby eliminating tumors without damaging normal tissues. https://en.globes.co.il/en/article-cancer-therapy-co-immpact-bio-raises-111m-1001399387 https://immpact-bio.com/

The Car-T cancer therapy invented by Israel’s Professor Zelig Eshhar (see here) is curing thousands of blood cancer patients. But the manual effort is hugely expensive. Now Israel’s ADVA Biotechnologies is developing a simpler, automated process. More lives will be … Continue reading →

According to the BBC, the CAR-T cancer therapy, (invented by Professor Zelig Eshhar of Israel’s Weizmann Institute) is curing 40% of UK lymphoma patients who were otherwise untreatable and terminal.  Amazing case stories – but doesn’t mention Israel of course! … Continue reading →

Israel’s Sheba hospital is partnering with Switzerland’s Lonza Group to fast-track production of the CAR-T cancer immunotherapy invented by Israeli scientists. Sheba is the first hospital to trial and refine Lonza’s Cocoon manufacturing platform for growing cells to treat hundreds … Continue reading →

The Israeli-developed CAR-T cancer treatment is one of NIS 460 million worth of new treatments added to Israel’s 2019 Health Basket. CAR-T has over 80% success rate, even in terminal cases. The new treatments will benefit an estimated 70,000 Israelis. … Continue reading →

Social worker Tali used to support staff at Hadassah’s Jerusalem Medical Center. Now her colleagues administer Hadassah’s CAR-T therapy (in Phase 1 trials see here) to hopefully cure Tali’s multiple myeloma. Hadassah hopes to develop cellular therapy for any type … Continue reading →

Tel Aviv University scientists have engineered the successful Israel-invented CAR-T cell therapy (see here) to also treat other cancers. They discovered a subset of immune system T cells (known as CD4+ T cells) will attract antibodies on solid tumors and … Continue reading →